EGFR and non-small cell lung carcinoma: The rapid development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring <i>EGFR</i> mutations including but not limited to exon 19 deletions (19 del) and point mutation L858R in exon 21.